The COS team will be attending ISPOR Europe, 2019

Linda Howard Uncategorized

The COS leadership team will be attending ISPOR Europe in Copenhagen in November as follows: Hudgens S, Pelletier C, Newton L, Howerter A, Gaines J, Keith S, Ung B, Udeze C, Evans C. Disease burden in patients with mild psoriasis: group concept mapping (PSS23). Presented at the International Society for Pharmacoeconomics and Outcomes Research Europe 2019; Wednesday 6 November, 09:30-14:00 …

COS will be attending ISOQOL

Linda Howard Uncategorized

Sunday 20 October Tuesday 22 October 2:29 pm – 2:37 pm (B202.4) Research Designs for Optimizing Data Collected from Multiple Sources in Real-World Populations Stacie Hudgens, Clinical Outcomes Solutions, Tucson, AZ, United States

The COS team will be attending ISPOR US, 2019

Linda Howard Uncategorized

The COS team will be presenting at ISPOR US in New Orleans in May as follows: Barsdorf A, Symonds T, Bush N. Introduction to Patient Reported Outcomes (short course).Course date: 18 May 2019; 08:00–12:00 Burbridge C, Kelly K, Garcia L, Dunaway Young S, Montes J, Johnson NB, Paradis A, Teynor M. Mapping a Qualitative Exploration of Meaningful Change in Later-onset …

COS announces oncology-focused research group

Linda Howard Uncategorized

In 2018, COS celebrated its 5th anniversary, this year, we are thrilled to announce the launch of Oncology Outcomes: Strategic Advisory Partnership. This oncology-focused research partnership led by Stacie Hudgens is launched in collaboration with global thought-leader, Alicyn Campbell, will expand the resources and expertise available to our clients.  Furthering allowing COS to be at the forefront of patient-related strategies …

Louise Newton

Implementing patient-reported outcome measures in clinical practice

Linda Howard Louise Newton

Article from Senior Director, Clinical Outcome Assessments, Louise Newton MSc. The use of patient-reported outcome (PRO) measures in clinical practice is increasing. Following the creation of a ‘User’s Guide to Implementing PRO Assessment in Clinical Practice’ by the International Society for Quality of Life Research (ISOQOL), volunteers from ISOQOL sought to create a Companion Guide to assist health care providers …

Recent presentations at ISPOR EU Barcelona from the COS team

Linda Howard Uncategorized

The COS team will be presenting at ISPOR as follows: Crawford B, Kim HR, Newton L, Symonds T. Roadblocks and resolutions: development of PRO instruments for multinational trials (Workshop 1).Presentation date: 12 November 2018; 11:15–12:15 Hudgens S, Newton L, Eremenco S, Crescioni M, Symonds T, Griffiths P,Knight-West O, Reasner DS, Byrom B, O’Donohoe P, Vallow S. Comparability of a provisioned …

Louise Newton

COS Senior Director, Louise Newton awarded JPRO Article of the Year

Linda Howard Louise Newton

We are excited to announce that Louise Newton’s article, “A comparison of three methods to generate a conceptual understanding of a disease based on the patients’ perspective.”  published in Journal of Patient-Reported Outcomes in 2017, has been awarded the ISOQOL Outstanding Article of the Year Award. The award recognizes and honors the single best article dedicated to health-related quality of …

Stacie Hudgens, CEO of Clinical Outcomes Solutions, on the Effects of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir Regimen on Health‐related Quality of Life for Patients with Hepatitis C

Linda Howard Stacie Hudgens

Stacie Hudgens, Chief Executive Officer, Strategic Lead Regulatory and Access, at COS, has an article published in Liver International: ‘Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C’ To view this article, please click here. To find out more about Stacie Hudgens, please click here.

Clinical Outcomes Solutions CEO Publishes Article on Understanding Health-related Quality of Life in an Ovarian Maintenance Clinical Trial

Linda Howard Stacie Hudgens

Stacie Hudgens MSc, Chief Executive Officer, Strategic Lead Regulatory and Access, has a manuscript published in The Lancet this month, entitled ‘Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial’. This is a paper focused on understanding health-related quality of life in an ovarian maintenance …